{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:43:36Z","timestamp":1790984616870,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,6,22]],"date-time":"2007-06-22T00:00:00Z","timestamp":1182470400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Mol Neurosci"],"published-print":{"date-parts":[[2007,9,10]]},"DOI":"10.1007\/s12031-007-0044-1","type":"journal-article","created":{"date-parts":[[2007,6,21]],"date-time":"2007-06-21T14:48:49Z","timestamp":1182437329000},"page":"114-119","source":"Crossref","is-referenced-by-count":53,"title":["F2-Isoprostanes as Biomarkers of Late-onset Alzheimer\u2019s Disease"],"prefix":"10.1007","volume":"33","author":[{"given":"Thomas J.","family":"Montine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,6,22]]},"reference":[{"key":"44_CR1","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1212\/WNL.42.9.1681","volume":"42","author":"P. V. Arriagada","year":"1992","unstructured":"Arriagada, P. V., Marzloff, K., & Hyma, B. T. (1992). Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer\u2019s disease. Neurology, 42, 1681\u20131688.","journal-title":"Neurology"},{"key":"44_CR2","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/archneur.1993.00540040011008","volume":"50","author":"L. Berg","year":"1993","unstructured":"Berg, L., McKeel, D. W., Miller, J. P., Baty, J., & Morris, J. C. (1993) Neuropathological indexes of Alzheimer\u2019s disease in demented and nondemented persons aged 80\u00a0years and older. Archives of Neurology, 50, 349\u2013358.","journal-title":"Archives of Neurology"},{"key":"44_CR3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1570-0232(03)00600-7","volume":"796","author":"K. C. Bohnstedt","year":"2003","unstructured":"Bohnstedt, K. C., Karlberg, B., Wahlund, L., Jonhagen, M. E., Basun, H., & Schmidt, S. (2003). Determination of isoprostanes in urine samples from Alzheimer patients using porous graphitic carbon liquid chromatography-tandem mass spectrometry. Journal of Chromatography B Analytical Technology Biomedical Life Science, 796, 11\u201319.","journal-title":"Journal of Chromatography B Analytical Technology Biomedical Life Science"},{"key":"44_CR4","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2105\/AJPH.88.9.1337","volume":"88","author":"R. Brookmeyer","year":"1998","unstructured":"Brookmeyer, R., Gray, S., & Kawas, C. (1998). Projections of Alzheimer\u2019s disease in the United States and the public health impact of delaying disease onset. American Journal of Public Health, 88, 1337\u20131342.","journal-title":"American Journal of Public Health"},{"key":"44_CR5","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ana.410340410","volume":"34","author":"H. A. Crystal","year":"1993","unstructured":"Crystal, H. A., Dickson, D. W., Sliwinski, M. J., Lipton, R. B., Grober, E., Marks-Nelson, H., et al. (1993) Pathological markers associated with normal aging and dementia in the elderly. Annals of Neurology, 34, 566\u2013573.","journal-title":"Annals of Neurology"},{"key":"44_CR6","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/00005072-199904000-00008","volume":"58","author":"D. G. Davis","year":"1999","unstructured":"Davis, D. G., Schmitt, F. A., Wekstein, D. R., & Markesbery, W. (1999) Alzheimer neuropathological alterations in aged cognitively normal subjects. Journal of Neuropathology and Experimental Neurology, 58, 376\u2013388.","journal-title":"Journal of Neuropathology and Experimental Neurology"},{"key":"44_CR7","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.neurobiolaging.2005.07.003","volume":"27","author":"M. J. Leon de","year":"2006","unstructured":"de Leon, M. J., Desanti, S., Zinkowski, R., Mehta, P. D., Pratico, D., Segal, S., et al. (2006). Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiology of Aging, 27, 394\u2013401.","journal-title":"Neurobiology of Aging"},{"key":"44_CR8","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2105\/AJPH.84.8.1261","volume":"84","author":"R. L. Ernst","year":"1994","unstructured":"Ernst, R. L., & Hay, J. W. (1994). The US economic and social costs of Alzheimer\u2019s disease revisited. American Journal of Public Health, 84, 1261\u20131264.","journal-title":"American Journal of Public Health"},{"key":"44_CR9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2307\/3350099","volume":"68","author":"D. A. Evans","year":"1990","unstructured":"Evans, D. A. (1990). Estimated prevalence of Alzheimer\u2019s disease in the United States. Milbank Quarterly, 68, 267\u2013289.","journal-title":"Milbank Quarterly"},{"key":"44_CR10","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0891-5849(99)00096-9","volume":"27","author":"C. Feillet-Coudray","year":"1999","unstructured":"Feillet-Coudray, C., Tourtauchaux, R., Niculescu, M., Rock, E., Tauveron, I., Alexandre-Gouabau, M. C., et al. (1999). Plasma levels of 8-epiPGF2alpha, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer\u2019s disease. Free Radical Biology & Medicine, 27, 463\u2013469.","journal-title":"Free Radical Biology & Medicine"},{"key":"44_CR11","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1006\/brcg.1996.0040","volume":"31","author":"D. Galasko","year":"1996","unstructured":"Galasko, D., Katzman, R., Salmon, D., & Hansen, L. (1996). Clinical and neuropathological findings in Lewy body dementias. Brain and Cognition, 31, 166\u2013175.","journal-title":"Brain and Cognition"},{"key":"44_CR12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1212\/WNL.54.1.105","volume":"54","author":"M. S. Green","year":"2000","unstructured":"Green, M. S., Kaye, J. A., & Ball, M. J. (2000) The Oregon brain aging study: Neuropathology accompanying health aging in the oldest old. Neurology, 54, 105\u2013113.","journal-title":"Neurology"},{"key":"44_CR13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J. Hardy","year":"2002","unstructured":"Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer\u2019s disease: Progress and problems on the road to therapeutics. Science, 297, 353\u2013356.","journal-title":"Science"},{"key":"44_CR14","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/archneur.56.6.713","volume":"56","author":"V. Haroutunian","year":"1999","unstructured":"Haroutunian, V., Purohit, D. P., Perl, D. P., Marin, D., Khan, K., Lantz, M., et al. (1999). Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. Archives of Neurology, 56, 713\u2013718.","journal-title":"Archives of Neurology"},{"key":"44_CR15","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/00005072-199812000-00009","volume":"57","author":"C. M. Hulette","year":"1998","unstructured":"Hulette, C. M., Welsh-Bohmer, K. A., Murray, M. G., Saunders, A. M., Mash, D. C., & McIntyre, L. M. (1998) Neuropathological and neuropsychological changes in \u201cnormal\u201d aging: Evidence for preclinical Alzheimer disease in cognitively normal individuals. Journal of Neuropathology and Experimental Neurology, 57, 1168\u20131174.","journal-title":"Journal of Neuropathology and Experimental Neurology"},{"key":"44_CR16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/archneur.1976.00500040001001","volume":"33","author":"R. Katzman","year":"1976","unstructured":"Katzman, R. (1976). Editorial: The prevalence and malignancy of Alzheimer disease. A major killer. Archives of Neurology, 33, 217\u2013218.","journal-title":"Archives of Neurology"},{"key":"44_CR17","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0197-2456(01)00189-1","volume":"23","author":"B. K. Martin","year":"2002","unstructured":"Martin, B. K., Meinert, C. L., & Breitner, J. C. (2002). Double placebo design in a prevention trial for Alzheimer\u2019s disease. Controlled Clinical Trials, 23, 93\u201399.","journal-title":"Controlled Clinical Trials"},{"key":"44_CR18","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1046\/j.1532-5415.2001.49231.x","volume":"49","author":"W. C. McCormick","year":"2001","unstructured":"McCormick, W. C., Hardy, J., Kukull, W. A., Bowen, J. D., Teri, L., Zitzer, S., et al. (2001). Healthcare utilization and costs in managed care patients with Alzheimer\u2019s disease during the last few years of life. Journal of the American Geriatrics Society, 49, 1156\u20131160.","journal-title":"Journal of the American Geriatrics Society"},{"key":"44_CR19","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1212\/WNL.52.3.562","volume":"52","author":"T. J. Montine","year":"1999","unstructured":"Montine, T. J., Beal, M. F., Cudkowicz, M. E., Brown, R. H., O\u2019Donnell, H., Margolin, R. A., et al. (1999a). Increased cerebrospinal fluid F2-isoprostane concentration in probable Alzheimer\u2019s disease. Neurology, 52, 562\u2013565.","journal-title":"Neurology"},{"key":"44_CR20","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1212\/WNL.52.5.1104","volume":"52","author":"T. J. Montine","year":"1999","unstructured":"Montine, T. J., Beal, M. F., Robertson, D., Cudkowicz, M. E., Biaggioni, I., O\u2019Donnell, H., et al. (1999b). Cerebrospinal fluid F2-isoprostanes are elevated in Huntington\u2019s disease. Neurology, 52, 1104\u20131105.","journal-title":"Neurology"},{"key":"44_CR21","doi-asserted-by":"crossref","first-page":"510","DOI":"10.5858\/2001-125-0510-CFATAF","volume":"125","author":"T. J. Montine","year":"2001","unstructured":"Montine, T. J., Kaye, J. A., Montine, K. S., McFarland, L., Morrow, J. D., & Quinn, J. F. (2001). CSF Ab42, tau, and F2-isoprostane concentrations in patients with Alzheimer\u2019s disease, other dementias, and age-matched controls. Archives of Pathology and Laboratory Medicine, 125, 510\u2013512.","journal-title":"Archives of Pathology and Laboratory Medicine"},{"key":"44_CR22","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/ana.410440322","volume":"44","author":"T. J. Montine","year":"1998","unstructured":"Montine, T. J., Markesbery, W. R., Morrow, J. D., & Roberts, L. J. (1998). Cerebrospinal fluid F2-isoprostanes are increased in Alzheimer\u2019s disease. Annals of Neurology, 44, 410\u2013413.","journal-title":"Annals of Neurology"},{"key":"44_CR23","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S0002-9440(10)65185-1","volume":"155","author":"T. J. Montine","year":"1999","unstructured":"Montine, T. J., Markesbery, W. R., Zackert, W., Sanchez, S. C., Roberts, L. J., & Morrow, J. D. (1999c). The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles, or with APOE genotype in Alzheimer\u2019s disease patients. American Journal of Pathology, 155, 863\u2013868.","journal-title":"American Journal of Pathology"},{"key":"44_CR24","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0891-5849(02)00807-9","volume":"33","author":"T. J. Montine","year":"2002","unstructured":"Montine, T. J., Neely, M. D., Quinn, J. F., Beal, M. F., Markesbery, W. R., Roberts, L. J., II, et al. (2002a). Lipid peroxidation in aging brain and Alzheimer\u2019s disease. Free Radical Biology & Medicine, 33, 620\u2013626.","journal-title":"Free Radical Biology & Medicine"},{"key":"44_CR25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/ana.10272","volume":"52","author":"T. J. Montine","year":"2002","unstructured":"Montine, T. J., Quinn, J. F., Milatovic, D., Silbert, L. C., Dang, T., Sanchez, S., et al. (2002b). Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer\u2019s disease. Annals of Neurology, 52, 175\u2013179.","journal-title":"Annals of Neurology"},{"key":"44_CR26","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/1531-8249(200012)48:6<950::AID-ANA23>3.0.CO;2-F","volume":"48","author":"T. J. Montine","year":"2000","unstructured":"Montine, T. J., Shinobu, L., Montine, K. S., Roberts, L. J., II, Beal, M. F., & Morrow, J. D. (2000). No difference in plasma or urine F2-isoprostanes among patients with Huntington\u2019s disease or Alzheimer\u2019s disease, and controls. Annals of Neurology, 48, 950.","journal-title":"Annals of Neurology"},{"key":"44_CR27","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1212\/WNL.53.7.1495","volume":"53","author":"T. J. Montine","year":"1999","unstructured":"Montine, T. J., Sidell, K. S., Crews, B. C., Markesbery, W. R., Marnett, L. J., Roberts, L. J., et al. (1999d). Elevated cerebrospinal fluid prostaglandin E2 levels in patients with probable Alzheimer\u2019s disease. Neurology, 53, 1495\u20131498.","journal-title":"Neurology"},{"key":"44_CR28","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1385\/JMN:17:2:101","volume":"17","author":"J. C. Morris","year":"2001","unstructured":"Morris, J. C., & Price, A. L. (2001). Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer\u2019s disease. Journal of Molecular Neuroscience, 17, 101\u2013118.","journal-title":"Journal of Molecular Neuroscience"},{"key":"44_CR29","doi-asserted-by":"crossref","unstructured":"Morrow, J. D., Hill, K. E., Burk, R. F., Nammour, T. M., Badr, K. F., & Roberts, L. J. (1990). A series of prostaglandin-like compounds produced in vivo in humans by a non-cyclooxygenase, free radical catalyzed mechanism. Proceedings of the National Academy of Sciences of the United States of America, 87, 9383\u20139387.","DOI":"10.1073\/pnas.87.23.9383"},{"key":"44_CR30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0076-6879(94)33019-0","volume":"233","author":"J. D. Morrow","year":"1994","unstructured":"Morrow, J. D., & Roberts, L. J., II (1994). Mass spectrometry of prostanoids: F2-isoprostanes produced by non-cyclooxygenase free radical catalyzed mechanism. Methods in Enzymology, 233, 163\u2013174.","journal-title":"Methods in Enzymology"},{"key":"44_CR31","doi-asserted-by":"crossref","unstructured":"Petersen, R., Doody, R., Kurz, A., Mohs, R., Morris, J., Rabins, P., et al. (2001). Current concepts in mild cognitive impairment. Archives of Neurology, 58, 1985\u20131982.","DOI":"10.1001\/archneur.58.12.1985"},{"key":"44_CR32","first-page":"57","volume":"21","author":"H. Petrovitch","year":"2000","unstructured":"Petrovitch, H., White, L. R., Izmirilian, G., Ross, G. W., Havlik, R. J., Markesbery, W., et al. (2000) Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: The HAAS. Honolulu\u2013Asia aging Study. Neurobiology of Aging, 21, 57\u201362.","journal-title":"Neurobiology of Aging"},{"key":"44_CR33","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF02536034","volume":"30","author":"N. A. Porter","year":"1995","unstructured":"Porter, N. A., Caldwell, S. E., & Mills, K. A. (1995) Mechanisms of free radical oxidation of unsaturated lipids. Lipids, 30, 277\u2013290.","journal-title":"Lipids"},{"key":"44_CR34","doi-asserted-by":"crossref","unstructured":"Pratico, D., Barry, O. P., Lawson, J. A., Adiyaman, M., Hwang, S. W., Khanapure, S. P., et al. (1998a). IPF2-alpha-I\u2014an index of lipid peroxidation in humans. Proceedings of the National Academy of Sciences, 95, 3449\u20133454.","DOI":"10.1073\/pnas.95.7.3449"},{"key":"44_CR35","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/1531-8249(200011)48:5<809::AID-ANA19>3.0.CO;2-9","volume":"48","author":"D. Pratico","year":"2000","unstructured":"Pratico, D., Clack, C. M., Lee, V. M. Y., Trojanowski, J. Q., Rokach, J., & FitzGerald, G. (2000) Increased 8,12-iso-iPF2a-IV in Alzheimer\u2019s disease: Correlation of a noninvasive index of lipid peroxidation with disease severity. Annals of Neurology, 48, 809\u2013812.","journal-title":"Annals of Neurology"},{"key":"44_CR36","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1001\/archneur.59.6.972","volume":"59","author":"D. Pratico","year":"2002","unstructured":"Pratico, D., Clark, C. M., Liun, F., Rokach, J., Lee, V. Y., & Trojanowski, J. Q. (2002). Increase of brain oxidative stress in mild cognitive impairment: A possible predictor of Alzheimer disease. Archives of Neurology, 59, 972\u2013976.","journal-title":"Archives of Neurology"},{"key":"44_CR37","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1096\/fasebj.12.15.1777","volume":"12","author":"D. Pratico","year":"1998","unstructured":"Pratico, D., Lee, V. M., Trojanowski, J. Q., Rokach, J., & Fitzgerald, G. A. (1998b). Increased F2-isoprostanes in Alzheimer\u2019s disease: Evidence for enhanced lipid peroxidation in vivo. FASEB Journal, 12, 1777\u20131784.","journal-title":"FASEB Journal"},{"key":"44_CR38","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0197-4580(91)90006-6","volume":"12","author":"J. L. Price","year":"1991","unstructured":"Price, J. L., Davis, P. B., Morris, J. C., & White, D. L. (1991). The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer\u2019s disease. Neurobiology of Aging, 12, 295\u2013312.","journal-title":"Neurobiology of Aging"},{"key":"44_CR39","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X","volume":"45","author":"J. L. Price","year":"1999","unstructured":"Price, J. L., & Morris, J. C. (1999). Tangles and plaques in nondemented aging and \u201cpreclinical\u201d Alzheimer\u2019s disease. Annals of Neurology, 45, 358\u2013368.","journal-title":"Annals of Neurology"},{"key":"44_CR40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3233\/JAD-2004-6110","volume":"6","author":"J. F. Quinn","year":"2004","unstructured":"Quinn, J. F., Montine, K. S., Moore, M., Morrow, J. D., Kaye, J. A., & Montine, T. J. (2004) Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer\u2019s disease. Journal of Alzheimer\u2019s Disease, 6, 93\u201397.","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"44_CR41","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0002-9440(10)63968-5","volume":"158","author":"E. E. Reich","year":"2001","unstructured":"Reich, E. E., Markesbery, W. R., Roberts, L. J., 2nd, Swift, L. L., Morrow, J. D., & Montine, T. (2001) Brain regional quantification of F-ring and D\/E-ring isoprostanes and neuroprostanes in Alzheimer\u2019s disease. American Journal of Pathology, 158, 293\u2013297.","journal-title":"American Journal of Pathology"},{"key":"44_CR42","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/ana.10161","volume":"51","author":"K. P. Riley","year":"2002","unstructured":"Riley, K. P., Snowdon, D. A., & Markesbery, W. R. (2002). Alzheimer\u2019s neurofibrillary pathology and the spectrum of cognitive function: Findings from the nun study. Annals of Neurology, 51, 567\u2013577.","journal-title":"Annals of Neurology"},{"key":"44_CR43","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1212\/WNL.55.3.370","volume":"55","author":"F. A. Schmitt","year":"2000","unstructured":"Schmitt, F. A., Davis, D. G., Wekstein, D. R., Smith, C. D., Ashford, J. W., & Markesbery, W. R. (2000). \u201cPreclinical\u201d AD revisited. Neuropathology of cognitively normal older adults. Neurology, 55, 370\u2013376.","journal-title":"Neurology"},{"key":"44_CR44","doi-asserted-by":"crossref","unstructured":"Strittmatter, W. J., & Roses A. D. (1995). Apolipoprotein E and Alzheimer\u2019s disease. Proceedings of the National Academy of Sciences, 92, 4725\u20134727.","DOI":"10.1073\/pnas.92.11.4725"},{"key":"44_CR45","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0025-7125(02)00003-2","volume":"86","author":"D. W. Tsuang","year":"2002","unstructured":"Tsuang, D. W., & Bird, T. D. (2002). Genetics of dementia. Medical Clinics of North America, 86, 591\u2013614.","journal-title":"Medical Clinics of North America"},{"key":"44_CR46","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0361-9230(01)00450-6","volume":"54","author":"E. E. Tuppo","year":"2001","unstructured":"Tuppo, E. E., Forman, L. J., Spur, B. W., Chan-Ting, R. E., Chopra, A., & Cavalieri, T. A. (2001). Sign of lipid peroxidation as measured in the urine of patients with probable Alzheimer\u2019s disease. Brain Research Bulletin, 54, 565\u2013568.","journal-title":"Brain Research Bulletin"},{"key":"44_CR47","first-page":"277","volume":"2","author":"E. Waddington","year":"1999","unstructured":"Waddington, E., Croft, K., Clarnette, R., Mori, T., & Martins, R. (1999). Plasma F2-isoprostane levels are increased in Alzheimer\u2019s disease: Evidence of increased oxidative stress in vivo. Alzheimer\u2019s Reports, 2, 277\u2013282.","journal-title":"Alzheimer\u2019s Reports"},{"key":"44_CR48","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1532-5415.1992.tb02072.x","volume":"40","author":"H. G. Welch","year":"1992","unstructured":"Welch, H. G., Walsh, J. S., & Larson, E. B. (1992). The cost of institutional care in Alzheimer\u2019s disease: Nursing home and hospital use in a prospective cohort. Journal of the American Geriatrics Society, 40, 221\u2013224.","journal-title":"Journal of the American Geriatrics Society"},{"key":"44_CR49","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1749-6632.2002.tb04794.x","volume":"977","author":"L. White","year":"2002","unstructured":"White, L., Petrovitch, H., Hardman, J., Nelson, J., Davis, D., Ross, G., et al. (2002). Cerebrovascular pathology and dementia in autopsied Honolulu\u2013Asia Aging Study participants. Annals of the New York Academy of Sciences, 977, 9\u201323.","journal-title":"Annals of the New York Academy of Sciences"},{"key":"44_CR50","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1749-6632.2000.tb06404.x","volume":"903","author":"J. H. Xuereb","year":"2000","unstructured":"Xuereb, J. H., Brayne, C., Dufouil, C., Gertz, H., Wischik, C., Harrington, C., et al. (2000). Neuropathological findings in the very old. Results from the first 101 brains of a population-based longitudinal study of dementing disorders. Annals of the New York Academy of Sciences, 903, 490\u2013496.","journal-title":"Annals of the New York Academy of Sciences"},{"key":"44_CR51","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archneur.61.1.82","volume":"61","author":"P. P. Zandi","year":"2004","unstructured":"Zandi, P. P., Anthony, J. C., Khachaturian, A. S., Stone, S. V., Gustafson, D., Tschanz, J. T., et al. (2004) Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: The Cache County Study. Archives of Neurology, 61, 82\u201388.","journal-title":"Archives of Neurology"}],"container-title":["Journal of Molecular Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12031-007-0044-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12031-007-0044-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12031-007-0044-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,15]],"date-time":"2021-08-15T06:24:22Z","timestamp":1629008662000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12031-007-0044-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,22]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,9,10]]}},"alternative-id":["44"],"URL":"https:\/\/doi.org\/10.1007\/s12031-007-0044-1","relation":{},"ISSN":["0895-8696","1559-1166"],"issn-type":[{"value":"0895-8696","type":"print"},{"value":"1559-1166","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,22]]}}}